Can-Fite BioPharma's Latest Developments
Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF) is making considerable strides in its mission to develop small-molecule drugs that address critical medical needs in oncology and inflammatory diseases. This innovative biotechnology company recently provided an update detailing its clinical trials and current financial status, reflecting a period of significant progress.
Advancements with Namodenoson
One of Can-Fite's flagship drug candidates, Namodenoson, is currently undergoing a pivotal Phase III clinical study aimed at treating advanced hepatocellular carcinoma (HCC) in patients with Child-Pugh B7 liver function. This phase of the research highlights the company's commitment to serving patients with considerable unmet medical needs within oncology. With no existing approved therapies for this particular patient demographic, the interim analysis is anticipated around the end of 2026. If the results are favorable, Can-Fite could potentially seek conditional approvals from regulatory authorities.
Clinical Trials for Metabolic Dysfunction
In addition, Can-Fite is actively recruiting participants for a Phase IIb study to investigate the efficacy of Namodenoson in addressing metabolic dysfunction-associated steatohepatitis (MASH). Following previous encouraging results from a Phase IIa trial demonstrating anti-inflammatory and anti-fibrotic benefits, this next phase aims to propel the development of this promising treatment.
Studies in Pancreatic Cancer
Moreover, Namodenoson is also undergoing evaluation in a Phase IIa clinical study focused on patients with pancreatic cancer who have not responded to first-line treatments. Patient enrollment for this study is nearing completion, contributing to the growing body of evidence Can-Fite is compiling regarding Namodenoson's potential.
Progress with Piclidenoson
Shifting attention to another valuable drug candidate, Piclidenoson is currently in a pivotal Phase III trial for psoriasis. Patients enrolled in this trial are receiving oral doses twice daily, with primary efficacy endpoints such as the Psoriasis Area and Severity Index (PASI) and Physician’s Global Assessment (PGA) being key measures for success. The interim analysis is expected in the second quarter of 2026, and anticipation is building around the potential findings from this research.
New Protocol for Rare Genetic Disease
Can-Fite has also advanced toward submitting a Phase II study protocol focusing on Lowe Syndrome, a rare genetic condition. Plans are underway to present this protocol to regulatory authorities in Italy and the European Medicines Agency in early 2026.
Current Financial Position
As of mid-2025, Can-Fite reported cash and cash equivalents, alongside short-term deposits, amounting to $6.45 million. The acquisition of additional capital is critical for continuing their innovative research. A public offering completed in July 2025 raised an aggregate gross of $5 million, followed by a successful $2.2 million raised through the company's ATM facility in November 2025.
Leadership Insight
Motti Farbstein, the Chief Executive Officer of Can-Fite BioPharma, asserted the company’s strategic drive to meet significant medical needs through their oral drug candidates. He emphasized their objective to generate meaningful clinical data in upcoming quarters by diligently executing their pivotal Phase III studies in liver cancer and psoriasis.
About Can-Fite BioPharma
Can-Fite BioPharma is positioned as a leader in advanced clinical stage drug development. With a comprehensive technology platform aimed at addressing multi-billion-dollar markets focused on cancer, liver, and inflammatory diseases, the company is preparing to make an indelible impact in these crucial fields. The promising lead drug, Piclidenoson, along with Namodenoson and CF602, reinforces their dedication to providing effective treatments that have demonstrated strong safety profiles in over 1,600 clinical trial participants.
Frequently Asked Questions
What is Namodenoson and what conditions does it target?
Namodenoson is a drug candidate being investigated for its potential to treat advanced liver cancer and metabolic dysfunction-associated steatohepatitis (MASH).
What is the status of the Phase IIb study for MASH?
The Phase IIb study for MASH is currently enrolling patients, building on encouraging results from earlier trials.
How is Piclidenoson being evaluated?
Piclidenoson is undergoing a pivotal Phase III trial for the treatment of psoriasis, with primary efficacy endpoints based on established industry measures.
What financial updates has Can-Fite disclosed recently?
As of mid-2025, Can-Fite reported $6.45 million in cash and completed a public offering that raised $5 million to support their operations.
How can I contact Can-Fite BioPharma for more information?
You can reach out to Can-Fite BioPharma via their email info@canfite.com or by phone at +972-3-9241114 for inquiries.
